Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890014 | PMC |
| http://dx.doi.org/10.3324/haematol.2022.281428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clozapine-associated perturbation of arachidonic acid metabolism: A future direction for clozapine-induced cardiotoxicity.
Toxicol Lett
September 2025
Department of Pharmacology and Clinical Pharmacology, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. Electronic address:
Clozapine is an effective antipsychotic medication utilised for treatment-resistant schizophrenia. However, clinical use of clozapine is limited due to the risk of cardiotoxicities, including clozapine-induced myocarditis. Oxidation of clozapine and reduction of clozapine-N-oxide can be catalysed by the cardio-selective cytochrome P450 (CYP) isoforms CYP2J2, CYP1A1 and CYP1B1, which are also reported to metabolise arachidonic acid.
View Article and Find Full Text PDFAn updated insight into the effect of β-adrenergic receptor antagonists (β-blockers) on respiratory function in asthma patients: a systematic review and meta-analysis.
Front Physiol
July 2025
Department of Immunopathology, Faculty of Medicine, Division of Biomedical Science, Medical University of Lodz, Lodz, Poland.
Background: This study aimed to provide an updated assessment of the changes in respiratory function after β-adrenergic receptor antagonists (β-blockers) administration in asthma patients. The main assumption of the study was to use new methodological and statistical approaches not previously applied in this field in systematic reviews and meta-analyses.
Methods: To select studies, PubMed/Medline, Embase, ClinicalTrials.
Beta-Blockers and Cutaneous Melanoma Outcomes: A Systematic Review and Random-Effects Meta-Analysis.
Pigment Cell Melanoma Res
January 2025
Dermatology Research Centre, Frazer Institute, The University of Queensland, Brisbane, Australia.
Beta-blockers have generated an exciting discourse for their potential as a cheap, safe, and effective adjunctive therapy for cutaneous melanoma patients, but the field remains murky. This systematic review investigates the association between beta-blocker use and survival outcomes in cutaneous melanoma patients. We reviewed 12 studies with 21,582 patients in a network meta-analysis and found a benefit between beta-blocker use and disease-free survival but no other significant association for melanoma-specific or overall survival.
View Article and Find Full Text PDFObesity and Sympathetic Overactivity in Young Individuals With Hypertension: Clinical Perspective of Indian Healthcare Providers.
Cureus
November 2024
Scientific Services, USV Private Limited, Mumbai, IND.
Introduction: To understand the current clinical practices followed by healthcare professionals (HCPs) among populations with hypertension and obesity with sympathetic overactivity and develop strategies to improve the management of hypertension.
Methods: A standard questionnaire was formulated based on high sympathetic overactivity and/or obesity in young patients with hypertension to gather information on the perception and practices of HCPs toward the management of young patients with hypertension who have high sympathetic overactivity and/or obesity. HCPs throughout India were selected.
Current Evidence and Future Perspectives in the Medical Management of Vascular Ehlers-Danlos Syndrome: Focus on Vascular Prevention.
J Clin Med
July 2024
Department of Clinical and Experimental Sciences, Division of Internal Medicine, ASST Spedali Civili Brescia, University of Brescia, 25123 Brescia, Italy.
Article Synopsis
- - Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic disorder caused by mutations in the gene for type III collagen, leading to fragile blood vessels and serious complications like aneurysms or ruptures, particularly affecting medium-sized arteries.
- - Previously, vEDS was associated with a high mortality rate and an average life expectancy of around 50 years, but recent advancements in medical awareness and treatment have improved patient outcomes significantly.
- - Current treatments, particularly the use of celiprolol, a specific heart medication, have shown promise in reducing vascular incidents in vEDS patients; however, more research is needed to fully understand its benefits, and other potential therapeutic avenues are being explored for future treatment. *